Lead Product(s): ARO-XDH
Therapeutic Area: Musculoskeletal Product Name: ARO-XDH
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Horizon Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 21, 2021
Arrowhead will conduct all activities through preclinical stages of development of the siRNA therapeutic, ARO-XDH. Horizon will receive a worldwide exclusive license to ARO-XDH and will be wholly responsible for clinical development and commercialization.
Lead Product(s): AM3101
Therapeutic Area: Musculoskeletal Product Name: AM3101
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Photon Fund
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 25, 2021
The proceeds from the financing will enable Amplicore to complete the preclinical development of its two leading products, AM3101 and AM1101, and position the company for the next round of financing.